Literature DB >> 2726676

Dehydration kinetics of prostaglandin E1 in a lipid emulsion.

D L Teagarden1, B D Anderson, W J Petre.   

Abstract

The overall dehydration kinetics of prostaglandin E1 (PGE1) in a lipid emulsion at 35 degrees C were found to fit a model whereby the kapparent measured at each pH is simply the sum of the product of the fraction of the PGE1 at the interface, fi, and the rate constant at the interface, ki, plus the product of the fraction of the PGE1 in the aqueous phase, faq, and the rate constant in the aqueous phase, kaq. The values for fi and faq were reported earlier as a function of pH at 35 degrees C. The kaq and kapparent were experimentally determined as a function of pH at 35 degrees C. The ki was indirectly determined from the stability data in the emulsion. Microscopic rate constants for dehydration of PGE1 in the aqueous phase and interface at 35 degrees C were estimated from the experimental data. Based on the kinetic evaluation performed, it appears that the dehydration kinetics might be manipulated by the addition of charged surface active agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2726676     DOI: 10.1023/a:1015909432300

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Kinetics of dehydration and isomerization of prostaglandins E 1 and E 2 .

Authors:  D C Monkhouse; L Van Campen; A J Aguiar
Journal:  J Pharm Sci       Date:  1973-04       Impact factor: 3.534

2.  Total rate equation for decomposition of prostaglandin E2.

Authors:  G F Thompson; J M Collins; L M Schmalzried
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

3.  Anti-inflammatory effects of indomethacin ester incorporated in a lipid microsphere.

Authors:  Y Mizushima; Y Wada; Y Etoh; K Watanabe
Journal:  J Pharm Pharmacol       Date:  1983-06       Impact factor: 3.765

4.  Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man.

Authors:  Y Mizushima; A Yanagawa; K Hoshi
Journal:  J Pharm Pharmacol       Date:  1983-10       Impact factor: 3.765

5.  Determination of the pH-dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltration.

Authors:  D L Teagarden; B D Anderson; W J Petre
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

6.  On the mechanism of dehydration of a beta-hydroxycyclopentanone analogue of prostaglandin E1.

Authors:  H K Lee; H J Lambert; R L Schowen
Journal:  J Pharm Sci       Date:  1984-03       Impact factor: 3.534

7.  Lipid microspheres as novel drug carriers.

Authors:  Y Mizushima
Journal:  Drugs Exp Clin Res       Date:  1985

8.  Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).

Authors:  S Otomo; Y Mizushima; H Aihara; K Yokoyama; M Watanabe; A Yanagawa
Journal:  Drugs Exp Clin Res       Date:  1985

9.  Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.

Authors:  K Hoshi; Y Mizushima; S Kiyokawa; A Yanagawa
Journal:  Drugs Exp Clin Res       Date:  1986
  9 in total
  3 in total

1.  Entrapping efficiency and drug release profile of an oil-in-water (o/w) emulsion formulation using a polydimethylsiloxane-coated glass bead assay.

Authors:  T Minagawa; Y Kohno; T Suwa; A Tsuji
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

2.  Absorption and disposition of colloidal drug delivery systems. I. High-performance liquid chromatographic (HPLC) analysis of a cyclosporin emulsion.

Authors:  S J Corvari; R G Hollenbeck; J Leslie; K I Plaisance; D Young
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.

Authors:  Yongwoo Jang; Woori Kim; Pierre Leblanc; Chun-Hyung Kim; Kwang-Soo Kim
Journal:  Exp Mol Med       Date:  2021-01-21       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.